Results 31 to 40 of about 8,581 (194)

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol

European Psychiatry, 2023
Introduction During the last decade there has been a resurgence of interest on the use of psychedelics as novel treatments for mental disorders, including treatment-resistant depression (TRD). Psilocybin, the chemical component of “magic mushrooms”, has
M. I. Husain, D. M. Blumberger, D. J. Castle, S. M. Kloiber, A. Ortiz, J. D. Rosenblat, B. H. Mulsant   +6 more
doaj   +1 more source

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings. [PDF]

Int J Methods Psychiatr Res
ABSTRACT Objectives For English, the validated part of Psychedelic Experience Scale (PES48) is a four‐factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and ...
Stocker K, Hartmann M, Barrett FS, Richards WA, Sepeda ND, Ley L, Becker AM, Holze F, Liechti ME.   +8 more
europepmc   +2 more sources

Community interest survey findings: 2022 report

, 2022
A survey to better understand community interest in accessing psilocybin services, in applying for licensure for one of the four license types, and in training program approval.

core  

Oregon Psilocybin Advisory Board rapid evidence review and recommendations

, 2021
authors: the Oregon Psilocybin Evidence Review Writing Group, Atheir I. Abbas, MD, PhD, Angela Carter, ND, Thomas Jeanne, MD, MPH, Rachel Knox, MD, MBA, P.

core  

De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli

Microbial Biotechnology
Psilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depression, underscoring its clinical importance.
Zhangrao Huang, Yongpeng Yao, Rouyu Di, JianChao Zhang, Yuanyuan Pan, Gang Liu   +5 more
doaj   +1 more source

Will psilocybin lose its magic in the clinical setting?

Therapeutic Advances in Psychopharmacology, 2022
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what ...
Caroline Hayes, Mourad Wahba, Stuart Watson   +2 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Recreational Drug Use at a Music Festival: A Dual Approach Using Hair Biomarkers Analysis and Participant Self‐Reported Drug Use

Drug Testing and Analysis, EarlyView.
Combined self‐report and hair analysis in festival attendees (n = 249) revealed substantial discrepancies in drug use reporting, particularly for stimulants and dissociatives. This integrated approach enhances detection of poly‐drug use and provides a more reliable basis for monitoring and harm‐reduction strategies.
A. Y. Simão, T. Rosado, M. Barroso, M. Andraus, E. Gallardo   +4 more
wiley   +1 more source

Cultural and anthropological review of resources

, 2022
prepared by Kirstin Yeomans, Graduate Research Assistant, Oregon Psilocybin Services Section.Title from PDF caption (viewed on July 19, 2022).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository ...

core  

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

Nature Communications
Psilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders.
Cassandra J. Hatzipantelis, Min Liu, Adam Love, Sadie J. Leventhal, Hero Maera, Srinidhi Viswanathan, Emily Avetisyan, Liana Belinsky, McKenna M. Rangel, Nina J. Jain, Max Kelly, Claire Copeland, Yara A. Khatib, Oliver Fiehn, David E. Olson, Danielle S. Stolzenberg   +15 more
doaj   +1 more source